Quinn T Ostrom1,2, David J Cote3,4,5, Mustafa Ascha6, Carol Kruchko1, Jill S Barnholtz-Sloan1,7. 1. Central Brain Tumor Registry of the United States, Hinsdale, Illinois. 2. Section of Epidemiology and Population Sciences, Department of Medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas. 3. Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 4. Computational Neurosciences Outcomes Center, Brigham and Women's Hospital, Boston, Massachusetts. 5. Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 6. Center for Clinical Investigation, Case Western Reserve University School of Medicine, Cleveland, Ohio. 7. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Abstract
Importance: Glioma is the most commonly occurring malignant brain tumor in the United States, and its incidence varies by age, sex, and race or ethnicity. Survival after brain tumor diagnosis has been shown to vary by these factors. Objective: To quantify the differences in incidence and survival rates of glioma in adults by race or ethnicity. Design, Setting, and Participants: This population-based study obtained incidence data from the Central Brain Tumor Registry of the United States and survival data from Surveillance, Epidemiology, and End Results registries, covering the period January 1, 2000, to December 31, 2014. Average annual age-adjusted incidence rates with 95% CIs were generated by glioma histologic groups, race, Hispanic ethnicity, sex, and age groups. One-year and 5-year relative survival rates were generated by glioma histologic groups, race, Hispanic ethnicity, and insurance status. The analysis included 244 808 patients with glioma diagnosed in adults aged 18 years or older. Data were collected from January 1, 2000, to December 31, 2014. Data analysis took place from December 11, 2017, to January 31, 2018. Results: Overall, 244 808 patients with glioma were analyzed. Of these, 150 631 (61.5%) were glioblastomas, 46 002 (18.8%) were non-glioblastoma astrocytomas, 26 068 (10.7%) were oligodendroglial tumors, 8816 (3.6%) were ependymomas, and 13 291 (5.4%) were other glioma diagnoses in adults. The data set included 137 733 males (56.3%) and 107 075 (43.7%) females. There were 204 580 non-Hispanic whites (83.6%), 17 321 Hispanic whites (7.08%), 14 566 blacks (6.0%), 1070 American Indians or Alaska Natives (0.4%), and 5947 Asians or Pacific Islanders (2.4%). Incidences of glioblastoma, non-glioblastoma astrocytoma, and oligodendroglial tumors were higher among non-Hispanic whites than among Hispanic whites (30% lower overall), blacks (52% lower overall), American Indians or Alaska Natives (58% lower overall), or Asians or Pacific Islanders (52% lower overall). Most tumors were more common in males than in females across all race or ethnicity groups, with the great difference in glioblastoma where the incidence was 60% higher overall in males. Most tumors (193 329 [79.9%]) occurred in those aged 45 years or older, with differences in incidence by race or ethnicity appearing in all age groups. Survival after diagnosis of glioma of different subtypes was generally comparable among Hispanic whites, blacks, and Asians or Pacific Islanders but was lower among non-Hispanic whites for many tumor types, including glioblastoma, irrespective of treatment type. Conclusions and Relevance: Incidence of glioma and 1-year and 5-year survival rates after diagnosis vary significantly by race or ethnicity, with non-Hispanic whites having higher incidence and lower survival rates compared with individuals of other racial or ethnic groups. These findings can inform future discovery of risk factors and reveal unaddressed health disparities.
Importance: Glioma is the most commonly occurring malignant brain tumor in the United States, and its incidence varies by age, sex, and race or ethnicity. Survival after brain tumor diagnosis has been shown to vary by these factors. Objective: To quantify the differences in incidence and survival rates of glioma in adults by race or ethnicity. Design, Setting, and Participants: This population-based study obtained incidence data from the Central Brain Tumor Registry of the United States and survival data from Surveillance, Epidemiology, and End Results registries, covering the period January 1, 2000, to December 31, 2014. Average annual age-adjusted incidence rates with 95% CIs were generated by glioma histologic groups, race, Hispanic ethnicity, sex, and age groups. One-year and 5-year relative survival rates were generated by glioma histologic groups, race, Hispanic ethnicity, and insurance status. The analysis included 244 808 patients with glioma diagnosed in adults aged 18 years or older. Data were collected from January 1, 2000, to December 31, 2014. Data analysis took place from December 11, 2017, to January 31, 2018. Results: Overall, 244 808 patients with glioma were analyzed. Of these, 150 631 (61.5%) were glioblastomas, 46 002 (18.8%) were non-glioblastoma astrocytomas, 26 068 (10.7%) were oligodendroglial tumors, 8816 (3.6%) were ependymomas, and 13 291 (5.4%) were other glioma diagnoses in adults. The data set included 137 733 males (56.3%) and 107 075 (43.7%) females. There were 204 580 non-Hispanic whites (83.6%), 17 321 Hispanic whites (7.08%), 14 566 blacks (6.0%), 1070 American Indians or Alaska Natives (0.4%), and 5947 Asians or Pacific Islanders (2.4%). Incidences of glioblastoma, non-glioblastoma astrocytoma, and oligodendroglial tumors were higher among non-Hispanic whites than among Hispanic whites (30% lower overall), blacks (52% lower overall), American Indians or Alaska Natives (58% lower overall), or Asians or Pacific Islanders (52% lower overall). Most tumors were more common in males than in females across all race or ethnicity groups, with the great difference in glioblastoma where the incidence was 60% higher overall in males. Most tumors (193 329 [79.9%]) occurred in those aged 45 years or older, with differences in incidence by race or ethnicity appearing in all age groups. Survival after diagnosis of glioma of different subtypes was generally comparable among Hispanic whites, blacks, and Asians or Pacific Islanders but was lower among non-Hispanic whites for many tumor types, including glioblastoma, irrespective of treatment type. Conclusions and Relevance: Incidence of glioma and 1-year and 5-year survival rates after diagnosis vary significantly by race or ethnicity, with non-Hispanic whites having higher incidence and lower survival rates compared with individuals of other racial or ethnic groups. These findings can inform future discovery of risk factors and reveal unaddressed health disparities.
Authors: Jill S Barnholtz-Sloan; John L Maldonado; Vonetta L Williams; William T Curry; Elizabeth A Rodkey; Frederick G Barker; Andrew E Sloan Journal: J Neurooncol Date: 2007-05-26 Impact factor: 4.130
Authors: Felix Sahm; David Reuss; Christian Koelsche; David Capper; Jens Schittenhelm; Stephanie Heim; David T W Jones; Stefan M Pfister; Christel Herold-Mende; Wolfgang Wick; Wolf Mueller; Christian Hartmann; Werner Paulus; Andreas von Deimling Journal: Acta Neuropathol Date: 2014-08-21 Impact factor: 17.088
Authors: Quinn T Ostrom; Haley Gittleman; Carol Kruchko; David N Louis; Daniel J Brat; Mark R Gilbert; Valentina I Petkov; Jill S Barnholtz-Sloan Journal: J Neurooncol Date: 2016-07-14 Impact factor: 4.130
Authors: Elysia M Alvarez; Theresa H Keegan; Emily E Johnston; Robert Haile; Lee Sanders; Paul H Wise; Olga Saynina; Lisa J Chamberlain Journal: Cancer Date: 2017-09-22 Impact factor: 6.860
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Michael Opoku-Darko; Stefan T Lang; James Artindale; J Gregory Cairncross; Robert J Sevick; John J P Kelly Journal: J Neurosurg Date: 2017-10-06 Impact factor: 5.115
Authors: Melissa Z Braganza; Cari M Kitahara; Amy Berrington de González; Peter D Inskip; Kimberly J Johnson; Preetha Rajaraman Journal: Neuro Oncol Date: 2012-09-05 Impact factor: 12.300
Authors: Quinn T Ostrom; Kathleen M Egan; L Burt Nabors; Travis Gerke; Reid C Thompson; Jeffrey J Olson; Renato LaRocca; Sajeel Chowdhary; Jeanette E Eckel-Passow; Georgina Armstrong; John K Wiencke; Jonine L Bernstein; Elizabeth B Claus; Dora Il'yasova; Christoffer Johansen; Daniel H Lachance; Rose K Lai; Ryan T Merrell; Sara H Olson; Siegal Sadetzki; Joellen M Schildkraut; Sanjay Shete; Richard S Houlston; Robert B Jenkins; Margaret R Wrensch; Beatrice Melin; Christopher I Amos; Jason T Huse; Jill S Barnholtz-Sloan; Melissa L Bondy Journal: Int J Cancer Date: 2019-04-22 Impact factor: 7.396
Authors: Chenan Zhang; Quinn T Ostrom; Helen M Hansen; Julio Gonzalez-Maya; Donglei Hu; Elad Ziv; Libby Morimoto; Adam J de Smith; Ivo S Muskens; Cassie N Kline; Zalman Vaksman; Hakon Hakonarson; Sharon J Diskin; Carol Kruchko; Jill S Barnholtz-Sloan; Vijay Ramaswamy; Francis Ali-Osman; Melissa L Bondy; Michael D Taylor; Catherine Metayer; Joseph L Wiemels; Kyle M Walsh Journal: Neuro Oncol Date: 2020-11-26 Impact factor: 12.300
Authors: Eudocia Q Lee; Ugonma N Chukwueke; Shawn L Hervey-Jumper; John F de Groot; Jose Pablo Leone; Terri S Armstrong; Susan M Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E Friday; Maryam Fouladi; Nancy U Lin; David Macdonald; Minesh P Mehta; Marta Penas-Prado; Michael A Vogelbaum; Solmaz Sahebjam; David Sandak; Martin van den Bent; Michael Weller; David A Reardon; Patrick Y Wen Journal: Neuro Oncol Date: 2019-09-06 Impact factor: 12.300
Authors: David J Cote; Quinn T Ostrom; Haley Gittleman; Kelsey R Duncan; Travis S CreveCoeur; Carol Kruchko; Timothy R Smith; Meir J Stampfer; Jill S Barnholtz-Sloan Journal: Cancer Date: 2019-06-17 Impact factor: 6.860
Authors: Shilpa Bhatia; Sanjana Bukkapatnam; Benjamin Van Court; Andy Phan; Ayman Oweida; Jacob Gadwa; Adam C Mueller; Miles Piper; Laurel Darragh; Diemmy Nguyen; Ahmed Gilani; Michael Knitz; Thomas Bickett; Adam Green; Sujatha Venkataraman; Rajeev Vibhakar; Diana Cittelly; Sana D Karam Journal: Mol Carcinog Date: 2020-06-22 Impact factor: 4.784
Authors: David M Peereboom; Tyler J Alban; Matthew M Grabowski; Alvaro G Alvarado; Balint Otvos; Defne Bayik; Gustavo Roversi; Mary McGraw; Pengjing Huang; Alireza M Mohammadi; Harley I Kornblum; Tomas Radivoyevitch; Manmeet S Ahluwalia; Michael A Vogelbaum; Justin D Lathia Journal: JCI Insight Date: 2019-11-14
Authors: Meijing Wu; Jason Miska; Ting Xiao; Peng Zhang; J Robert Kane; Irina V Balyasnikova; James P Chandler; Craig M Horbinski; Maciej S Lesniak Journal: J Neurooncol Date: 2019-01-31 Impact factor: 4.130